Biography for Nick Paul Taylor
Nick Taylor, UK Correspondent
Nick Taylor is a freelance journalist with more than six years' experience of reporting on the global biopharma industry. Since graduating with a biology degree from the University of York, Nick has written for numerous healthcare publications, including Nature BioPharma Dealmakers, Life Science Leader and Outsourcing-Pharma. You can contact him at firstname.lastname@example.org and follow him on Twitter at @NickPaulTaylor.
Articles by Nick Paul Taylor
NuMedii has landed a deal that could validate its data-driven approach to drug discovery. Allergan is the company to give a shot to NuMedii, signing up to source a flow of potential treatments for psoriasis from the Stanford University spinout.
Pacific Biosciences has stepped up the fight for the sequencing market with the introduction of an instrument that is smaller, cheaper and higher throughput than the model it replaces.
The set of studies running on Apple's ResearchKit is continuing to expand and improve. Yale School of Medicine and The Icahn School of Medicine at Mount Sinai are the latest to step up their use of the platform, rolling out a new heart condition study and refining an asthma app, respectively.
Cloud Pharmaceuticals and Therametrics have hooked up to apply their computing and software capabilities to a central nervous system (CNS) R&D program. The plan is to use Cloud's computing platform to design drugs to inhibit targets identified by Therametrics' software.
Genomics England has enlisted Berg Health to support its 100,000 Genomes Project. The agreement gives Berg a seat alongside GlaxoSmithKline, Roche and other notable drugmakers on the GENE Consortium, an initiative set up to investigate how data from the project can facilitate drug discovery.
Bayer has set up a system to manage its omics data analysis workflow. The system is the result of Bayer's collaboration with Genedata, which has provided its data management and analysis software to a platform that also draws on the capabilities of the open-source iRODS.
BioClinica is continuing the rapid evolution that began 18 months ago when its new owners merged it with CCBR-SYNARC. The latest step in the process is the buyout of Synowledge, a provider of pharmacovigilance and regulatory affairs services and accompanying IT support.
The deal makes ZS Bristol's primary vendor in the sector, allowing the Big Pharma to trim the list of vendors with which it works to analyze commercial data.
Federal officials are to prioritize making high-quality electronic health data more readily available to researchers over the next 5 years. Objectives include increased use of trial data in patient-focused outcomes studies, the application of health IT to improve clinical research and greater openness.